Raphael Pharmaceutical Inc. (RAPH) Research

Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life. Currently, the company's leading investigational drug candidate is being advanced for the management of rheumatoid arthritis. Furthermore, Raphael Pharma plans to broaden its pipeline to include more cannabinoid-based medicines aimed at various cancer types and other autoimmune conditions. The company's corporate headquarters are situated in Tel Aviv-Jaffa, Israel.

Market snapshot

Symbol
RAPH
Price
$1.40
Day change
0.00%
Market cap
$28.2M
P/E ratio
-23.98x
52-week range
0.052-1.4
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Avicanna Inc. (AVCNF)
  • INDVR Brands Inc. (CAAOF)
  • Choom Holdings Inc. (CHOOF)
  • Elbit Imaging Ltd. (EMITF)
  • Molecule Holdings Inc. (EVRRF)
  • Global Pharmatech, Inc. (GBLP)
  • Isracann Biosciences Inc. (ISCNF)
  • MediPharm Labs Corp. (MEDIF)

Recent insider activity

  • Louria Hayon Igal — X-InTheMoney (350000 shares) on 2025-11-20
  • Louria Hayon Igal — X-InTheMoney (350000 shares) on 2025-11-20
  • Laor Zvi Laufer — trade (0 shares) on 2025-08-01
  • Eliya Yehuda — A-Award (200000 shares) on 2025-03-10
  • Eliya Yehuda — E-ExpireShort (202000 shares) on 2022-05-12

Open Raphael Pharmaceutical Inc. (RAPH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.